Hi Everyone
Just wonder what others think. Daclatasvir is no doubt the best pangenotypic NS5A DAA on the market to date, I guess that's my own opinion based on my own investigation.
My concern is that soon Gilead will be flogging velpatasvir as a competing NS5A pangenotypic to daclatasvir. Now given that Gilead own sofosbuvir it would stand to reason to suspect that most people on the planet will be offered sofosbuvir and velpatasvir. More so if indeed velpatasvir is a cheaper option to ledipasvir. My issue is that velpatasvir data doesn't look as good as daclatasvir or ledipasvir regardless of pangenotypic status.
Okay maybe I'm looking too close at this issue but I'm not convinced velpatasvir is an improvement to HCV treatment options. Em
PS I understand there is an NZ trial about to commence in Jan using sof/vel for 8 and 12 weeks and is offering this to F4s, crazy.
Geno 1b F2/3 snce early 80s. Treated in 2008_9 for 63 weeks on INF/Riba. Commence Sof/Dac on 6 October 2015 and completed 18 weeks of tx. UND at 4-6 weeks, UND at EOT, SVR 2, SVR 6 and SVR 12 on 6 May 2016.
